argenx SE (ARGNF)
OTCMKTS
· Delayed Price · Currency is USD
547.60
+0.42 (0.08%)
At close: Jul 2, 2025
argenx SE Revenue
argenx SE had revenue of $807.37M in the quarter ending March 31, 2025, with 95.72% growth. This brings the company's revenue in the last twelve months to $2.64B, up 82.13% year-over-year. In the year 2024, argenx SE had annual revenue of $2.25B with 77.22% growth.
Revenue (ttm)
2.64B
Revenue Growth
+82.13%
P/S Ratio
12.60
Revenue / Employee
1.65M
Employees
1,599
Market Cap
33.32B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.25B | 979.61M | 77.22% |
Dec 31, 2023 | 1.27B | 827.58M | 187.66% |
Dec 31, 2022 | 441.01M | -87.25M | -16.52% |
Dec 31, 2021 | 528.27M | 466.31M | 752.59% |
Dec 31, 2020 | 61.96M | -30.85M | -33.24% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo, Inc. | 1.73B |
Veradigm | 588.02M |
Elite Pharmaceuticals | 84.04M |
Tian'an Technology Group | 1.78M |
Glass House Brands | 215.62M |
American Oncology Network | 1.76B |
Northwest Biotherapeutics | 1.47M |
Silence Therapeutics | 27.70M |
argenx SE News
- 2 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX - PRNewsWire
- 7 days ago - Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years - Benzinga
- 8 days ago - Argenx's CIDP Challenge: A Safety Signal Points To Operational Refinement, Not Ruin - Seeking Alpha
- 9 days ago - FDA Flags Major Safety Concerns For Argenx's Nerve Disorder Drug, Stock Falls - Benzinga
- 9 days ago - FDA Flags Major Safety Concerns For Argenx's Nerve Disorder Drug, Stock Falls - Benzinga
- 9 days ago - argenx down 7% as FDA identifies possible safety signal with Vyvgart Hytrulo - Seeking Alpha
- 19 days ago - argenx gets EU nod for Vyvgart subcutaneous injection - Seeking Alpha
- 19 days ago - argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy - GlobeNewsWire